Aminolevulinic acid hydrochloride is under clinical development by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical and currently in Phase II for Cervical Intraepithelial Neoplasia (CIN). According to GlobalData, Phase II drugs for Cervical Intraepithelial Neoplasia (CIN) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Aminolevulinic acid hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Aminolevulinic acid hydrochloride overview

Aminolevulinic acid hydrochloride (ALA) is a second generation photodynamic drug. It is formulated as powder for topical route of administration. It is used to treatment for CA traditional areas, fill a gap in urethral orifice CA cure, become the best treatment for CA in preferred therapy.

It is under development for the treatment of cervical intraepithelial neoplasia infected by human papilloma virus (HPV), actinic keratosis, acne. It was also under development for basal cell carcinoma and as adjuvant therapy for the treatment brain gliomas.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical overview

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (FDZJ), a subsidiary of Shanghai Pharmaceutical Co Ltd, is a biopharmaceutical company that focuses on research, development, manufacturing and marketing of genetic engineering drugs. It primarily develops genetic engineering drugs, nanotechnology drugs, photodynamic technology drugs, and oral solid preparation technology drugs. The company’s key products include ALA (Aminolevulinic acid Hydrochloride), Hemoporfin for Injection and Doxorubicin liposome among others. It markets products across China. FDZJ is headquartered in Shanghai, China.

For a complete picture of Aminolevulinic acid hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.